News

Researchers narrowing in on early neuronal functioning stages of development, well before Huntington’s disease symptoms appear, believe they have found a potentially important path to intervening with the diabetes medication metformin. Their research was conducted in a mouse model of the disease. Metformin, an oral medication normally prescribed to patients…

Short huntingtin (HTT) protein fibers precede the formation of larger deposits that accumulate in the brains of those affected by Huntington’s disease, preclinical results reveal. These findings one day may help researchers predict the onset and course of the disease. The study, “mHTT Seeding Activity: A Marker of…

Huntington’s disease begins early, before birth, but symptoms tend to appear much later in life. Now, researchers working with mice have found a way to reverse so-called “pre-Huntington’s symptoms,” including abnormal nerve cell differentiation, with early therapeutic intervention. This could have important implications for future treatment strategies. The study, “Early postnatal…

Active Biotech. has regained global development and commercialization rights of laquinimod, an investigational immunotherapy for neurodegenerative diseases, including Huntington’s disease (HD) and multiple sclerosis (MS). The move came after Teva Pharmaceutical, the company that previously held laquinimod’s rights, decided not to continue its clinical development. After several years…

Researchers have found a direct link between abnormal protein accumulation in nerve cells — a hallmark of several neurodegenerative diseases, such as Parkinson’s and Alzheimer’s — and the regulation of gene activity in Huntington’s disease. According to researchers, both processes are influenced by autophagy, a mechanism used by cells to break…